Melanoma-associated antigen A4-specific T-cells co-expressing CD8 alpha - Adaptimmune
Alternative Names: ADP‑A2M4CD8; Autologous genetically modified ADP-A2M4CD8 cells; uza-celLatest Information Update: 13 Aug 2024
At a glance
- Originator Adaptimmune
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Gastric cancer; Oesophageal cancer; Ovarian cancer
- Phase I Solid tumours
Most Recent Events
- 30 May 2024 Adaptimmune and Galapagos NV agree to co-develop Melanoma-assocaiated antigen A4-specific T-cells co-expressing CD8 alpha
- 20 Mar 2024 Phase-I clinical trials in Solid tumours (In adults, In the elderly) in France (Parenteral) (NCT04044859)
- 20 Mar 2024 Phase-I clinical trials in Solid tumours (In adults, In the elderly) in United Kingdom (Parenteral) (NCT04044859)